Thermedical’s Groundbreaking SERF Ablation System Earns FDA’s Breakthrough Device Designation

WALTHAM, Mass.–([1])–Thermedical®[2], a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), today announced that it has received Breakthrough Device Designation from the U.S. Food & Drug Administration (FDA) for its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate® catheter. The FDA Breakthrough Devices Program[3] is intended to help patients receive more timely access to technologies that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.

Ventricular tachycardia[4], which is an abnormally rapid heart rhythm, is a leading cause of sudden cardiac death worldwide. Sudden cardiac death kills 325,000 U.S. adults annually, more than any other natural cause.

“Today, an estimated one million people who develop, or are likely to develop VT annually, have limited options for effective treatment and often suffer a very poor quality of life,” said Roy Tanaka[5], member of Thermedical’s board of directors. “Thermedical’s ablation technology will be transformational in clinical electrophysiology. It offers the potential for an entirely new therapy that could replace the standard-of-care treatment for VT.”

Implantable Cardioverter Defibrillators (ICD), which are electronic devices that constantly monitor a patient’s heart rhythm, are the current treatment for patients suffering from VT; however, this approach does not stop the progression of the disease or provide a cure. In addition, ICDs can be costly and painful. During a VT episode, the ICD delivers energy to the heart muscle via a powerful shock or antitachycardia pacing to help the heart beat normally again. Today, VT patients with ICDs and who experience persistent VT episodes may be treated with conventional RF ablation – a lengthy procedure with a moderate success rate of approximately 50 percent1.

Thermedical’s SERF[6] ablation system provides a new form of biological heat transfer that is 20 times more effective at transferring heat than conventional ablation methods. Compared to conventional VT ablation catheters, the Durablate catheter[7] can accurately control the ablation size and treat tissue that is deeper in the heart wall, which is where life-threatening arrhythmias that cause VT are often located.

According to William G. Stevenson, M.D[8]., professor of medicine at Vanderbilt University Medical Center, and a principal investigator in the SERF VT Early Feasibility Study[9] (EFS), “Preliminary results are encouraging. I am optimistic that this therapy will offer new hope for patients with VT who have failed all other therapeutic options.”

The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Durablate catheter to treat VT. The trial is underway in the U.S[10]. and Canada[11].

“We are pleased to have the FDA recognize the novelty and potential for our therapeutic approach in treating VT as a breakthrough technology and look forward to a continued productive relationship with FDA to expedite access to patients who have few to no therapeutic options,” said Trena Depel[12], vice president of clinical, regulatory and quality at Thermedical.

About Thermedical

Thermedical[13] is a privately held company founded by Massachusetts Institute of Technology (MIT) Hyperthermia Center alumni, Michael G. Curley, Ph.D. and Patrick S. Hamilton, Ph.D., based in Waltham, Mass. Under a Massachusetts Life Sciences Center Small Business Matching Grant (SBMG) Award, multiple NIH* Small Business Innovation Research (SBIR) Grants, and Series A venture funding, the company has developed thermal-ablation systems to treat VT and solid tumors. For more information, visit www.thermedical.com[14].

* Research reported in this publication was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number R44HL132746 and R44HL63535. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

1http://www.onlinejacc.org/content/accj/67/6/684.full.pdf[15]

References

  1. ^ (www.businesswire.com)
  2. ^ Thermedical® (cts.businesswire.com)
  3. ^ Breakthrough Devices Program (cts.businesswire.com)
  4. ^ Ventricular tachycardia (cts.businesswire.com)
  5. ^ Roy Tanaka (cts.businesswire.com)
  6. ^ SERF (cts.businesswire.com)
  7. ^ Durablate catheter (cts.businesswire.com)
  8. ^ William G. Stevenson, M.D (cts.businesswire.com)
  9. ^ SERF VT Early Feasibility Study (cts.businesswire.com)
  10. ^ U.S (cts.businesswire.com)
  11. ^ Canada (cts.businesswire.com)
  12. ^ Trena Depel (cts.businesswire.com)
  13. ^ Thermedical (cts.businesswire.com)
  14. ^ www.thermedical.com (cts.businesswire.com)
  15. ^ http://www.onlinejacc.org/content/accj/67/6/684.full.pdf (cts.businesswire.com)

Source URL: Read More
The public content above was dynamically discovered – by graded relevancy to this site’s keyword domain name. Such discovery was by systematic attempts to filter for “Creative Commons“ re-use licensing and/or by Press Release distributions. “Source URL” states the content’s owner and/or publisher. When possible, this site references the content above to generate its value-add, the dynamic sentimental analysis below, which allows us to research global sentiments across a multitude of topics related to this site’s specific keyword domain name. Additionally, when possible, this site references the content above to provide on-demand (multilingual) translations and/or to power its “Read Article to Me” feature, which reads the content aloud to visitors. Where applicable, this site also auto-generates a “References” section, which appends the content above by listing all mentioned links. Views expressed in the content above are solely those of the author(s). We do not endorse, offer to sell, promote, recommend, or, otherwise, make any statement about the content above. We reference the content above for your “reading” entertainment purposes only. Review “DMCA & Terms”, at the bottom of this site, for terms of your access and use as well as for applicable DMCA take-down request.

Acquire this Domain
You can acquire this site’s domain name! We have nurtured its online marketing value by systematically curating this site by the domain’s relevant keywords. Explore our content network – you can advertise on each or rent vs. buy the domain. Buy@TLDtraders.com | Skype: TLDtraders | +1 (475) BUY-NAME (289 – 6263). Thousands search by this site’s exact keyword domain name! Most are sent here because search engines often love the keyword. This domain can be your 24/7 lead generator! If you own it, you could capture a large amount of online traffic for your niche. Stop wasting money on ads. Instead, buy this domain to gain a long-term marketing asset. If you can’t afford to buy then you can rent the domain.

About Us
We are Internet Investors, Developers, and Franchisers – operating a content network of several thousand sites while federating 100+ eCommerce and SaaS startups. With our proprietary “inverted incubation” model, we leverage a portfolio of $100M in valued domains to impact online trends, traffic, and transactions. We use robotic process automation, machine learning, and other proprietary approaches to power our content network. Contact us to learn how we can help you with your online marketing and/or site maintenance.

Share